Context Therapeutics (NASDAQ:CNTX) Given Buy Rating at D. Boral Capital

D. Boral Capital reaffirmed their buy rating on shares of Context Therapeutics (NASDAQ:CNTX) in a research report sent to investors on Tuesday morning,Benzinga reports. The firm currently has a $9.00 target price on the stock.

A number of other equities analysts also recently commented on CNTX. Wall Street Zen upgraded shares of Context Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday. Guggenheim reaffirmed a “buy” rating and set a $5.00 price target on shares of Context Therapeutics in a report on Tuesday. JonesTrading began coverage on Context Therapeutics in a research report on Monday, December 22nd. They set a “buy” rating and a $7.00 price objective for the company. Piper Sandler increased their price objective on Context Therapeutics from $4.00 to $7.00 and gave the company an “overweight” rating in a report on Tuesday. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Context Therapeutics in a research report on Wednesday, January 21st. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $6.60.

Context Therapeutics Stock Up 5.3%

Shares of Context Therapeutics stock opened at $3.18 on Tuesday. Context Therapeutics has a 52-week low of $0.49 and a 52-week high of $3.62. The company has a market capitalization of $292.18 million, a P/E ratio of -8.37 and a beta of 1.96. The company has a 50 day moving average of $2.41 and a 200 day moving average of $1.60.

Context Therapeutics (NASDAQ:CNTX) last announced its quarterly earnings data on Monday, March 23rd. The company reported ($0.14) EPS for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.04). As a group, research analysts anticipate that Context Therapeutics will post -0.51 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Context Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of CNTX. Virtu Financial LLC acquired a new position in Context Therapeutics in the fourth quarter valued at $43,000. XTX Topco Ltd increased its position in shares of Context Therapeutics by 858.8% during the fourth quarter. XTX Topco Ltd now owns 101,605 shares of the company’s stock worth $149,000 after purchasing an additional 91,008 shares in the last quarter. Quadrature Capital Ltd purchased a new stake in shares of Context Therapeutics in the 4th quarter valued at about $68,000. Millennium Management LLC purchased a new stake in shares of Context Therapeutics in the 4th quarter valued at about $3,824,000. Finally, Marshall Wace LLP boosted its position in shares of Context Therapeutics by 7,153.7% in the 4th quarter. Marshall Wace LLP now owns 2,593,198 shares of the company’s stock valued at $3,812,000 after purchasing an additional 2,557,448 shares during the period. 14.03% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about Context Therapeutics

Here are the key news stories impacting Context Therapeutics this week:

• Positive Sentiment: Multiple brokerages boosted ratings and price targets — Piper Sandler raised its price target to $7 and kept an “overweight” rating, Guggenheim reaffirmed a “buy” with a $5 target, and D. Boral Capital reaffirmed a “buy” with a $9 target. These notes increase upside expectations and likely helped buying interest. Analyst Notes
• Positive Sentiment: Clinical catalysts and cash runway: Context expects Phase 1a interim data for CTIM‑76 (CLDN6 x CD3) in June 2026 and for CT‑95 (MSLN x CD3) in September 2026, with CT‑202 Phase 1 dosing planned in Q3 2026. Management reported $66.0M cash as of 12/31/25, which it says funds operations into mid‑2027 — a near‑term runway that supports continued development. Full-Year 2025 Results
• Neutral Sentiment: Company updated its corporate presentation highlighting the evolving T‑cell engager pipeline; useful for investors but not an immediate price driver by itself. Pipeline Update
• Neutral Sentiment: Short‑interest reports in late March show anomalous “0 shares / NaN” values across multiple feeds — likely a data/reporting error rather than a true change in short interest; treat these entries with caution.
• Negative Sentiment: Quarterly EPS miss: Context reported -$0.14 EPS for the quarter, missing the consensus -$0.10 estimate — a near‑term negative that can weigh on sentiment. Earnings Release / Market Reaction
• Negative Sentiment: Widening losses and lower cash vs. 2024: Net loss increased to $36.1M (from $26.7M) and cash fell to $66.0M from $94.4M a year earlier — increases R&D spend and burn risk, which could pressure the stock if upcoming data or financing plans disappoint. Financials & Milestones

About Context Therapeutics

Context Therapeutics (NASDAQ: CNTX) is a clinical-stage biopharmaceutical company focused on the discovery and development of precision therapies for genetically defined patient populations in oncology. The company’s research model centers on identifying novel targets and designing small-molecule and biologic candidates that address key drivers of tumor growth and resistance. Context Therapeutics leverages a biomarker-driven approach to maximize the probability of clinical response, tailoring its development programs to specific molecular subgroups within solid tumors.

With a pipeline advancing through early clinical trials, Context Therapeutics emphasizes strategic collaborations and academic partnerships to accelerate the translation of laboratory findings into patient-focused studies.